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Abstract 37 
Compelling genetic evidence links the amyloid precursor protein (APP) to Alzheimer’s 38 
disease (AD), and several theories have been advanced to explain the involvement of 39 
APP in AD.  A leading hypothesis proposes that a small amphipathic fragment of APP, 40 
the amyloid β-protein (Aβ), self-associates to form soluble aggregates which impair 41 
synaptic and network activity.  Here, we employed the most disease-relevant form of Aβ, 42 
protein isolated from AD brain.  Using this material, we show that the synaptotoxic 43 
effects of Aβ depend on expression of APP and that the Aβ-mediated impairment of 44 
synaptic plasticity is accompanied by pre-synaptic effects which disrupt the 45 
excitatory/inhibitory (E/I) balance.  The net increase in the E/I ratio, and inhibition of 46 
plasticity are associated with Aβ localizing to synapses and binding of soluble Aβ 47 
aggregates to synapses requires the expression of APP.  Taken together, our findings 48 
indicate a role for APP in AD pathogenesis beyond the generation of Aβ and suggest 49 
modulation of APP expression as a therapy for AD. 50 
  51 
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Significance Statement 52 
Here, we report on the plasticity-disrupting effects of Aβ isolated from AD brain and the 53 
requirement of APP for these effects.  We show that Aβ-containing AD brain extracts 54 
block hippocampal long-term potentiation (LTP), augment glutamate release probability 55 
and disrupt the excitation/inhibition balance.  Notably, these effects are associated with 56 
Aβ localizing to synapses, and genetic ablation of APP prevents both Aβ binding and 57 
Aβ-mediated synaptic dysfunctions.  Our results emphasize the importance of APP in 58 
AD and should stimulate new studies to elucidate APP-related targets suitable for 59 
pharmacological manipulation. 60 
61 
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Introduction 62 
Mutation, over-expression or altered processing of the amyloid precursor protein (APP) 63 
underlie all known monogenic cases of familial Alzheimer’s disease (fAD) (Tanzi, 2012; 64 
Guerreiro and Hardy, 2014).  Although the physiological roles of APP are not fully 65 
understood, a myriad of studies indicate that APP plays a role in synaptic plasticity, 66 
dendritic morphogenesis, and neuroprotection (Muller and Zheng, 2012).  Membrane-67 
tethered APP can act as a cell-adhesion molecule linking the pre-and post-synapse 68 
(Soba et al., 2005) and APP has been shown to regulate synaptic vesicle proteins, 69 
synaptic transmission and plasticity (Dawson et al., 1999; Lassek et al., 2013; Fanutza 70 
et al., 2015; Lassek et al., 2016).  In the rat dentate gyrus (DG), APP expression is 71 
known to change during memory consolidation (Conboy et al., 2005) and 72 
intraventricular administration of anti-APP antibodies or antisense oligonucleotides 73 
results in profound amnesia (Doyle et al., 1990; Huber et al., 1993; Mileusnic et al., 74 
2000).  Notably, APP is a component of the presynaptic GABA-B1a receptor (GABAB1a-75 
R) complex (Bai et al., 2008; Schwenk et al., 2016) and neuron-type specific knock-out 76 
of APP indicates an important role for APP in GABAergic transmission and maintenance 77 
of the excitatory–inhibitory balance (Wang et al., 2014). 78 
APP is a complex molecule that undergoes substantial post-translational modification 79 
and processing as more than 10 different proteolytic fragments of APP have been 80 
identified.  Several of these are suggested to be pathogenic (Neve and McPhie, 2007; 81 
Yankner and Lu, 2009; Tamayev et al., 2012; Welzel et al., 2014; Willem et al., 2015), 82 
whereas others are neuroprotective (Mockett et al., 2017).  The fragment from which the 83 
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precursor protein derives its name, the amyloid β-protein (Aβ), is found in the tell-tale 84 
amyloid plaques which populate brains of individuals who die with AD.  Aβ comprises a 85 
family of APP-derived peptides that share a common core of ~30 amino acids (Walsh 86 
and Teplow, 2012) which are produced by the concerted action of two aspartyl 87 
proteases, β–secretase and -secretase (De Strooper, 2010).  Aβ peptides are prone to 88 
self-associate and multiple studies indicate that certain forms of Aβ adversely affect 89 
synaptic form and function (Li et al., 2009). 90 
The synaptotoxic activity of Aβ and the involvement of APP in synapse formation and 91 
activity are particularly relevant to AD since in vivo and postmortem studies indicate that 92 
synapse dysfunction and loss are prominent early features of AD (Scheff et al., 2006; 93 
Scheff et al., 2007; Johnson et al., 2012).  Acute studies in wild-type rodents show that 94 
non-fibrillar, water-soluble Aβ from a variety of sources are potent synaptotoxins 95 
(Lambert et al., 1998; Walsh et al., 2002; Cleary et al., 2005; Lesne et al., 2006; Klyubin 96 
et al., 2008; Minkeviciene et al., 2009; Kurudenkandy et al., 2014).  Furthermore, in vitro 97 
and in vivo studies demonstrate that the most disease-relevant form of non-fibrillar Aβ, 98 
Aβ extracted from the water-soluble phase of AD brain, inhibits long-term potentiation 99 
(LTP), facilitates long-term depression (LTD), reduces synaptic remodeling, and impairs 100 
memory consolidation (Shankar et al., 2008; Barry et al., 2011; Freir et al., 2011; 101 
Borlikova et al., 2013; Jo et al., 2014; Yang et al., 2017).  Here, we show that the block 102 
of LTP mediated by Aβ-containing AD brain extracts is accompanied by opposing 103 
changes in excitatory and inhibitory pre-synaptic release probabilities and consequent 104 
disruption of the excitation/inhibition (E/I) balance.  The net increase in the E/I ratio and 105 
inhibition of LTP require expression of APP and are associated with Aβ localizing to 106 
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synapses.  These findings suggest a link between Aβ toxicity and perturbation of the 107 
normal regulatory role of APP, and are consistent with prior studies which have imputed 108 
a role for APP in Aβ toxicity (White et al., 1998; Lorenzo et al., 2000; Shaked et al., 109 
2006; Sola Vigo et al., 2009; Fogel et al., 2014; Kirouac et al., 2017).  In light of these 110 
results we suggest that down-regulation of APP expression or modulation of its 111 
interaction with synaptotoxic Aβ species should be investigated as an approach to treat 112 
AD. 113 
  114 
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Materials and Methods 115 
Reagents 116 
All chemicals and reagents were purchased from Sigma-Aldrich unless otherwise noted.  117 
Synthetic Aβ1–42 was synthesized and purified using reverse-phase HPLC by Dr. 118 
James I. Elliott at the ERI Amyloid laboratory (Oxford, CT, USA).  Peptide mass and 119 
purity (>99%) were confirmed by reverse-phase HPLC and electrospray/ion trap mass 120 
spectrometry.  N-terminally extended (NTE) -31Aβ-40 was prepared and purified as 121 
described previously (Mc Donald et al., 2015) and recombinant Aeta-alpha (A, 122 
APP505-611) was a gift from Drs. Willem and Haass (Ludwig-Maximillian University, 123 
Munich). 124 
 125 
Antibodies 126 
The antibodies used and their source are described in Table 1. 127 
 128 
Preparation of human brain extracts 129 
All human specimens were obtained and used in accordance with the Partner’s 130 
Institutional Review Board (Protocol: Walsh BWH 2011).  Brain tissue was obtained 131 
from 2 of individuals (referred to as AD1 and AD2) who died with AD and one individual 132 
who died free of AD (designated NC).  AD1 was an 87-year-old man who 9 months prior 133 
to death had scored 23 on the MMSE and designated Braak stage 4 at postmortem had 134 
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pathological changes consistent with mild AD.  AD2 was a 68-year-old female with end-135 
stage AD.  Three years prior to death AD2 scored 23 on the MMSE, but in her last 136 
weeks she was unable to answer questions other than to provide her first name.  Upon 137 
postmortem examination there was evidence of fulminant amyloid and neurofibrillary 138 
tangle pathology which was designated Braak stage V/VI.  Neither AD1 nor AD2 had a 139 
family history of AD.  NC was a 58-year-old female who died free of AD symptoms and 140 
pathology.  AD1 and NC has post-mortem intervals (PMI) of 18 hours, and AD had a 141 
PMI of 12 hours.  Aqueous extracts of brain were prepared by homogenizing cortical 142 
tissue in a buffer which we refer to as artificial cerebrospinal fluid base buffer (aCSF-B) 143 
(124 mM NaCl, 2.8 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, pH 7.4).  aCSF-B is 144 
the core buffer used in subsequent electrophysiology experiments.  Whole frozen 145 
temporal cortex was left at 4oC until the tissue was sufficiently soft to cut.  Meninges 146 
and large blood vessels were removed and gray matter dissected from white matter.  147 
The total amount of gray matter obtained was between 12-14 g.  Two gram lots of tissue 148 
were diced using a razor blade and then homogenized in 10 ml of ice-cold aCSF-B 149 
(containing 5 mM Ethylenediaminetetraacetic acid, 1 mM Ethyleneglycoltetraacetic acid, 150 
5 μg/ml Leupeptin, 5 μg/ml Aprotinin, 2 μg/ml Pepstatin, 120 μg/ml Pefabloc and 5 mM 151 
NaF) with 25 strokes of a Dounce homogenizer (Fisher, Ottawa, Canada).  152 
Homogenates from 6, 2 g lots were pooled and centrifuged at 198,000 g and 4°C for 153 
110 minutes in a SW 41-Ti rotor (Beckman Coulter, Fullerton, CA).  The upper 90% of 154 
supernatant was dialyzed (using Slide-A-Lyzer™ G2 Dialysis Cassettes, 2K MWCO, 155 
Fisher Scientific) against fresh aCSF-B to remove bioactive small molecules and drugs.  156 
Dialysis was performed at 4oC against a 100-fold excess of buffer with buffer changed 3 157 
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times over a 36 hour period.  Thereafter, extracts were divided into 2 parts: 1 portion 158 
was immunodepleted (ID) of Aβ by 3 rounds of 12 hour incubations with the anti-Aβ 159 
antibody, AW7, plus Protein A sepharose (PAS) beads at 4 oC (Freir et al., 2011).  The 160 
second portion was treated in an identical manner, but this time incubated with pre-161 
immune serum plus PAS beads.  Samples were cleared of beads and 0.5 ml aliquots 162 
stored at -80oC until used for biochemical or electrophysiological experiments.  Samples 163 
were thawed only once prior to use. 164 
 165 
Preparation of amyloid-derived diffusible ligands (ADDLs) 166 
Amyloid-derived diffusible ligands (ADDLs) were prepared essentially as described 167 
previously (Freir et al., 2011).  Hexafluoro-2-propanol (HFIP; 222 l) was added to 1 mg 168 
of A(1–42) in a 2 ml low-binding microcentrifuge tube to produce a peptide 169 
concentration of 1 mM.  The solution was split into two tubes, incubated at 37°C for 1 170 
hour and mixed by vortexing every 10 minutes.  The HFIP was gently evaporated under 171 
a nitrogen stream with rotation of the tube to ensure formation of an even film of peptide 172 
on the lower walls of the tube.  Dried peptide films were stored over desiccant at 20°C 173 
for a minimum of 14 hours.  The peptide film from each tube was then dissolved in 20 l 174 
of anhydrous DMSO (Life Technologies, Woburn, MA) and 5 l lots of the DMSO 175 
mixture was added stepwise to 980 l of F-12 medium (Life Technologies), with 176 
vortexing between each addition.  The resulting solution was incubated at 4°C for 48 177 
hours and then centrifuged at 16,000 g for 10 minutes.  The upper 95% of the 178 
supernatant was transferred to a new microcentrifuge tube and the protein 179 
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concentration determined using the extinction coefficient, ε275 = 1361 M
-1 cm-1 (O’Malley 180 
et al., 2014).  Aliquots were then immediately frozen on dry ice and stored at -80°C. 181 
 182 
Characterization of ADDLs 183 
The size and morphology of structures present in the ADDLs preparation were 184 
investigated using negative contrast electron microscopy and analytical size exclusion 185 
chromatography (SEC).  Samples were stained and visualized essentially as described 186 
previously (Betts et al., 2008).  An aliquot of the ADDL preparation (50 l) was diluted 187 
1:1 with F12 media and then adsorbed (10 μl) onto formvar-coated copper grids 188 
(Electron Microscopy Sciences).  After 1 minute, 10 μl 0.25% glutaraldehyde was added 189 
and incubated for 1 minute.  Thereafter, grids were wicked dry using filter paper, 190 
washed twice with MilliQ water and then stained with 1% uranyl-acetate for 2 minutes.  191 
Grids were allowed to air dry for at least 10 minutes, stored at room temperature and 192 
then examined using a 1200EX microscope (JEOL). 193 
A separate aliquot of ADDLs (50 l) was thawed and loaded on to a Superdex 75 194 
3.2/300 PE column (GE Healthcare) eluted in PBS pH 7.4 at 0.8 ml/min using a 195 
Shimadzu HPLC system. 196 
 197 
Preparation of synthetic peptides used for Western blotting 198 
A peptide was dissolved in 50 mM ammonium bicarbonate, pH 8.5, diluted to 10 199 
ng/μl, aliquoted and stored frozen at -80°C.  Aβ1-42 and -31Aβ40 which are prone to 200 
aggregate were treated to depolymerize any pre-existing aggregates.  Briefly, peptides 201 
were dissolved in 50 mM Tris-HCl, pH 8.5, containing 7 M guanidium-HCl (GuHCl) and 202 
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5 mM ethylenediaminetetraacetic acid (EDTA) at a concentration of 1 mg/ml and 203 
incubated at room temperature (RT) overnight.  Samples were then centrifuged for 30 204 
minutes at 16,000 g and chromatographed on a Superdex 75 10/300 column eluted at 205 
0.5 ml/min with 50 mM ammonium bicarbonate, pH 8.5.  The concentration of the peak 206 
fraction for each sample was determined by absorbance at 275 nm.  The peptide was 207 
then diluted to 10 ng/μl, aliquoted and stored frozen at -80°C. 208 
 209 
Immunoprecipitation/Western blotting (IP/WB) of Aβ in brain extracts 210 
Extracts were first pre-cleared with PAS beads to minimize non-specific interactions in 211 
the subsequent IP.  One ml aliquots of extracts were incubated with 15 μl PAS beads 212 
for 1 hour at 4°C with gentle shaking.  PAS beads were removed by centrifugation 213 
(4000 g for 5 minutes) and the supernatant divided into 0.5 ml aliquots.  Each aliquot 214 
was incubated with 10 l of AW7 and 15 μl PAS beads overnight at 4°C with gentle 215 
shaking.  Aβ-antibody-PAS complexes were collected by centrifugation and washed as 216 
previously described (Shankar et al., 2011).  The immunoprecipitated (IP’d) Aβ was 217 
eluted by boiling in 18 μl of 1 × sample buffer (50 mM Tris, 2% w/v SDS, 12% v/v 218 
glycerol with 0.01% phenol red) and electrophoresed on hand poured, 15 well 16% 219 
polyacrylamide tris-tricine gels.  A, Aβ1-42 and -31Aβ40 were run as loading 220 
controls and protein transferred onto 0.2 M nitrocellulose at 400 mA and 4oC for 2 221 
hour.  Blots were microwaved in PBS and Aβ detected using the anti-Aβ40 and anti-222 
Aβ42 antibodies, 2G3 and 21F12, and bands visualized using a Li-COR Odyssey 223 
infrared imaging system (Li-COR, Lincoln, NE).  To determine if AW7 IP’d other APP 224 
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metabolites (e.g. APPs, N-terminally extended Aβ or A peptides) from AD brain 225 
extracts, certain blots were developed with 6E10 (Table 1). 226 
 227 
MSD Aβ immunoassays 228 
Samples were analyzed for Aβ content using 2 distinct assay formats: the Aβx-42 assay 229 
that preferentially detects Aβ42 monomers and the oAssay that preferentially detects Aβ 230 
oligomers and aggregates (Mably et al., 2015; Yang et al., 2015). Immunoassays were 231 
performed using the Meso Scale Discovery (MSD) platform and reagents from Meso 232 
Scale (Rockville, MD).  The Aβx-42 assay uses mAb m266 (3 μg/ml) for capture and 233 
biotinylated 21F12 (1 μg/ml) for detection, and the oAssay uses mAb 1C22 (3 μg/ml) for 234 
capture and biotinylated 3D6 (1 μg/ml) for detection.  Samples, standards and blanks 235 
were loaded in duplicate and analyzed as described previously (Mably et al., 2015). 236 
Since Guanidine Hydrochloride (GuHCl) effectively disaggregates high molecular weight 237 
Aβ species (Mably et al., 2015), samples were analyzed both with and without 238 
incubation in 5 M GuHCl.  Analysis of samples in the absence of GuHCl allows the 239 
measurement of native Aβ42 monomer using the Aβx-42 assay, and native Aβ 240 
aggregates using the oAssay.  Analysis of samples treated with GuHCl allows detection 241 
of disassembled aggregates with Aβx-42 assay.  To dissociate aggregates, 20 μl of 242 
extract was incubated overnight with 50 μl of 7 M GuHCl at 4°C.  Thereafter samples 243 
were diluted 1:10 with assay diluents so that the final GuHCl concentration was 0.5 M.  244 
Aβ standards were prepared in tris-buffered saline (TBS), pH 7.4 containing 0.5 M 245 
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GuHCl, 0.05% Tween 20 and 1% Blocker A so that both standards and samples 246 
contained the same final concentration of GuHCl. 247 
 248 
Mice 249 
All animal procedures were performed in accordance with the National Institutes of 250 
Health Policy on the Use of Animals in Research and were approved by the Harvard 251 
Medical School Standing Committee on Animals.  Wild-type (WT) C57BL/6 mice were 252 
purchased from the Jackson Laboratory (Bar Harbor, ME).  APP KO mice on a C57BL/6 253 
background and littermate WT controls were obtained from the Young-Pearse lab 254 
(Callahan et al., 2017).  A second line of APP KO mice were purchased from the 255 
Jackson Laboratory (APPtm1Dbo/J, The Jackson Laboratory, Bar Harbor, ME) (Zheng et 256 
al., 1995) and for certain experiments these animals were bred with WT C57BL/6 mice 257 
to generate APP (+/-) hemizygotes.  Animals were housed in a room with a 12 hour 258 
light/dark circadian cycle with ad libitum access to food and water.  Mice were 259 
genotyped by PCR prior to use, and both male and female mice were used.  In certain 260 
experiments, upon completion of electrophysiological recordings, brain slices were used 261 
for Western blotting or array tomography. 262 
 263 
Brain slice preparation 264 
Two to three months old male and female animals were anaesthetized with isoflurane 265 
and decapitated.  Brains were rapidly removed and immediately immersed in ice-cold 266 
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(0-4°C) artificial cerebrospinal fluid (aCSF).  The aCSF contained (in mM): 124 NaCl, 3 267 
KCl, 2.4 CaCl2, 2 MgSO4·7H2O, 1.25 NaH2PO4, 26 NaHCO3 and 10 D-glucose, and was 268 
equilibrated with 95% O2 and 5% CO2, pH 7.4, 310 mOsm.  Coronal brain slices (350 269 
µm), including hippocampus (Wang et al., 2008), were prepared using a Leica VT1000 270 
S vibratome (Leica Biosystems Inc, Buffalo Grove, IL), transferred to an interface 271 
chamber and incubated at 34 ± 5°C for 20 minutes and then kept at room temperature 272 
for 1 hour before recording. 273 
 274 
Long-term potentiation (LTP) recording 275 
Brain slices were transferred to a submerged recording chamber and perfused (10 276 
ml/min) with oxygenated (95% O2 and 5% CO2) aCSF 10 minutes before 277 
electrophysiological recordings.  Brian slices were visualized using an infrared and 278 
differential interference contrast camera (IR-DIC camera, Hitachi, Japan) mounted on 279 
an upright Olympus microscope (Olympus, Tokyo, Japan).  Recording electrodes were 280 
pulled from borosilicate glass capillaries (Sutter Instruments, Novato, CA) using a 281 
micropipette puller (Model P-97; Sutter Instruments, Novato, CA) with resistance ~2 MΩ 282 
when filled with aCSF.  To induce field excitatory post-synaptic potentials (fEPSPs) in 283 
the hippocampal CA1, a tungsten wire stimulating electrode (FHC, Inc., Bowdoin, ME) 284 
was placed on the Schaffer collaterals of the CA3 and a recording electrode was placed 285 
at least 300 m away on the striatum radiatum of the CA1.  The initial 10-40 % slope of 286 
fEPSPs were calculated.  Test stimuli were delivered once every 20 seconds (0.05 Hz) 287 
and the stimulus intensity was adjusted to produce a baseline fEPSP of 30–40% of the 288 
maximal response.  A stable baseline was recorded for at least 10 minutes prior to 289 
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addition of sample.  Thirty minutes following application of sample, LTP was induced by 290 
theta burst stimulation (TBS).  This involved 3 trains, each of 4 pulses delivered at 100 291 
Hz, 10 times, with an interburst interval of 200 milli-second with a 20 second interval 292 
between each train.  Field potentials were recorded using a Multiclamp amplifier 293 
(Multiclamp 700B; Molecular Devices, Sunnyvale, CA) coupled to a Digidata 1440A 294 
digitizer.  Signal was sampled at 10 kHz and filtered at 2 kHz and data were analyzed 295 
using Clampex 10 software (Molecular Devices, Sunnyvale, CA). 296 
 297 
Whole-cell patch clamp recording 298 
Brain slices were prepared from male and female WT and APP KO mice (1-2 months 299 
old) as described above for LTP experiments but using a cutting solution that contained 300 
sucrose (in mM: 72 sucrose, 83 NaCl, 2.5 KCl, 1 NaH2PO4, 3.3 MgSO4·7H2O, 26.2 301 
NaHCO3, 22 dextrose, and 0.5 CaCl2) saturated with 95% O2 and 5% CO2, pH 7.4, 310 302 
mOsm (Wang et al., 2015).  Slices were incubated in oxygenated slicing solution for 20 303 
minute, and held at room temperature for a further 40 minute prior to recording.  Slices 304 
were transferred to a submerged recording chamber and perfused (10 ml/min) with 305 
oxygenated (95% O2 and 5% CO2) aCSF for 30 minute at room temperature.  Whole-306 
cell recordings were made from the somata of CA1 pyramidal neurons visualized using 307 
an IR-DIC camera mounted on an upright Olympus microscope (Olympus, Tokyo, 308 
Japan).  Patch pipettes (4–7MΩ) were filled with an internal solution containing (in mM): 309 
120 CsGluconate, 5 MgCl2, 0.6 EGTA, 30 HEPES, 4 MgATP, 0.4 Na2GTP, 10 310 
phosphocreatine-Tris, 5 N-(2,6-Dimethylphenylcarbamoylmethyl)triethylammonium 311 
bromide (QX-314); 290 mOsm; pH was adjusted to 7.2 with CsOH.  Signal was 312 
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acquired using a Multiclamp amplifier (Multiclamp 700B; Molecular Devices, Sunnyvale, 313 
CA) with Clampex 10 software (Molecular Devices, Sunnyvale, CA), sampled at 10 kHz 314 
and filtered at 2 kHz.  Data were stored on a PC after digitization by an A/D converter 315 
(Digidata 1440A, Molecular Devices, Sunnyvale, CA) for offline analysis.  Membrane 316 
potential was corrected for the liquid junction potential of 13.7 mV.  Neurons with 317 
negative resting membrane potential less than -60 mV were not analyzed.  Input 318 
resistance and patching access resistance were continuously monitored during the 319 
experiment and cells which exhibited more than 15–20% changes in these parameters 320 
were excluded from analysis. 321 
In order to preserve a relatively intact neuronal circuit, no receptor antagonists were 322 
used. Spontaneous excitatory post-synaptic currents (sEPSCs) were collected at a 323 
membrane holding potential of -70 mV, which is close to the calculated reverse potential 324 
of GABA.  In order to measure the excitatory and inhibitory input on the same neuron, 325 
the spontaneous inhibitory post-synaptic currents (sIPSCs) were also measured on the 326 
same neuron but this time the holding potential was increased to 5-10 mV, a potential 327 
close to the reverse potential of excitatory input, without visual negative deflection.  328 
Recorded neuronal activities were detected as described previously (Lillis et al., 2015)  329 
by custom software (DClamp: available at www.ieeg.org/?q=node/34).  Integrated 330 
excitatory conductance (sEPSCs, GE) and integrated inhibitory conductance (sIPSCs, 331 
GI) were calculated as previously reported  

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(Slomowitz et al., 2015). 333 
 18 
 
Preparation of mouse brain homogenates and detection of APP 334 
Certain brain slices from wild-type and APP knock-out mice were frozen immediately 335 
after completion of electrophysiological recording (Figures 4, 5 and 6) and stored at -336 
80oC until analyzed.  Tissue (~0.1 mg) was homogenized in 5 volumes (w/v) of ice-cold 337 
20 mM Tris-HCl, containing 150 mM NaCl and 1%TX-100 (TBS-Tx), pH 7.4 containing 338 
protease inhibitors and centrifuged at 100,000 g and 4°C for 78 minutes in a TLA-55 339 
rotor (Beckman Coulter, Fullerton, CA).  The upper 90% of the supernatant was 340 
removed, aliquoted and stored at -80°C pending analysis.  Ten μg of total protein was 341 
boiled in 1 × sample buffer (62.5 mM Tris, 1% w/v SDS, 10% v/v glycerol, 0.01% phenol 342 
red and 2% β-mercaptoethanol) for 5 minutes and electrophoresed on hand poured, 15 343 
well 10% polyacrylamide tris-glycine gels.  Gels were rinsed in transfer buffer (10% 344 
methanol, 192 mM Glycine and 25 mM Tris) and proteins electroblotted onto 0.2 μM 345 
nitrocellulose membranes at 400 mA and 4°C for 2.5 hours.  Membranes were 346 
developed using the anti-APP antibody, 22C11, and bands visualized using a Li-COR 347 
Odyssey infrared imaging system (Li-COR, Lincoln, NE). 348 
 349 
Array tomography (AT) imaging of mouse brain slices 350 
Upon completion of electrophysiology recordings certain brain slices from wild-type and 351 
APP knock mice (Figures 4, 5 and 6) were processed for array tomography (Koffie et al., 352 
2009; Pickett et al., 2016).  Slices were fixed in PBS containing 4% paraformaldehyde 353 
and 2.5% sucrose at 4°C overnight.  Samples were then washed three times (10 354 
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minutes each) in cold wash buffer (PBS containing 3.5% sucrose and 50 mM glycine), 355 
and the hippocampus dissected out under a Leica Wild M3Z Stereozoom Microscope 356 
(Heerbrugg, Swizerland).  Thereafter hippocampi were dehydrated using an ethanol 357 
gradient of: 50%, 70%, 95% and 100%.  Tissue was then placed into a solution of 1:1 358 
ethanol: LR White resin (Electron Microscopy Sciences) for 5minute and then washed 3 359 
times with LR White.  Tissue was incubated overnight at 4°C in LR White, embedded in 360 
a gelatin capsule and polymerized overnight at 53°C.  Three embedded blocks per 361 
condition were cut into ribbons of 70 nm sections on an ultracut microtome (Leica) using 362 
a Jumbo Histo Diamond Knife (Diatome).  Ribbons were collected on gelatin-coated 363 
glass coverslips, stained with antibodies and imaged along the ribbon.  Two ribbons per 364 
slice were collected and one was stained for PSD95 and 1C22 and the other for 365 
synapsin-1 and 1C22.  Primary antibodies were 1C22 (1:50), rabbit anti-PSD95 (3450P, 366 
Cell Signaling, at 1:50), and rabbit anti-synapsin-1 (AB1543P, Millipore, at 1:100).  367 
Secondary antibodies donkey anti-mouse 488 (A21202) and donkey anti-rabbit 594 368 
(A21207) were from Invitrogen and used at 1:50. 369 
Two image stacks per ribbon were collected from the stratum radiatum using a Zeiss 370 
axio Imager Z2 epifluorescent microscope with a 63X 1.4NA Plan Apochromat objective.  371 
Images were acquired with a CoolSnap digital camera and AxioImager software with 372 
array tomography macros (Carl Zeiss, Ltd, Cambridge UK).  Images from each set of 373 
serial sections were compiled to create a 3D stack and aligned using ImageJ 374 
multistackreg macros (Kay et al., 2013).  Regions of interest (10 μm x 10 μm) were 375 
selected, cropped and thresholded in Image J (Schindelin et al., 2012; Ollion et al., 376 
2013) (Figure 1).  Custom MATLAB macros were used to remove single slice punctuate, 377 
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count synaptic punctuate and assess co-localization with 1C22 (a minimum of 50% 378 
overlap between 1C22 and synaptic punctuate was required to be designated as co-379 
localization).  All custom analysis macros will be freely available on 380 
http://datashare.is.ed.ac.uk after publication. 381 
 382 
Data analysis and Statistical test 383 
Figures showing IP/WB and MSD Aβ immunoassay data are representative of at least 2 384 
independent experiments.  For electrophysiological experiments, the AD, ID-AD and 385 
aCSF samples were coded and tested in an interleaved manner to avoid variances in 386 
animals or slice quality influencing results.  Slices in each group came from different 387 
animals unless otherwise noted.  Electrophysiological data were analyzed offline by 388 
pclamp 10.2 (Molecular Devices, Sunnyvale, CA) and tested with One-way or Two-way 389 
analysis of variance (ANOVA) with Bonferroni post-hoc tests or student’s t-tests (# 390 
p<0.05, ## p< 0.01, and ### p< 0.001).  A Kolmogorov–Smirnov (K–S) test was used to 391 
compute differences in distributions of sEPSCs and sIPSCs.  Array tomography was 392 
analyzed using SPSS Version 22.  A single percent co-localization for each parameter 393 
was calculated for each slice from approximately 41 regions of interest and ≈7,500 394 
synapses (~3,500 pre-synapses and ~3,500 post-synapses) were analyzed per slice 395 
and tested with a Kruskal-Wallis with Dunns post-hoc test.  Electrophysiology data are 396 
shown as means ± SEM.  Array tomography data is shown as medians ± the 397 
interquartile range, each point representing all synapses measured within 1 slice.  398 
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Analyses of the same sample using different slices are considered technical replicates 399 
and analysis of extracts from different AD brains are considered biological replicates. 400 
401 
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Results 402 
We previously reported that aqueous extracts of certain end-stage AD brains block 403 
hippocampal LTP in vivo and in vitro (Shankar et al., 2008; Barry et al., 2011; Freir et al., 404 
2011; Jo et al., 2014).  Here we further investigated the mechanism of this effect and 405 
the requirement of endogenous APP. 406 
 407 
The water-soluble extract from AD brain contains both Aβ monomers and 408 
oligomers and blocks LTP in a manner dependent on Aβ 409 
Brain extracts were prepared as described and a portion was immunodepleted (ID) of 410 
Aβ or mock-ID with pre-immune rabbit serum.  Here, the mock-ID extract is referred to 411 
as the AD sample, and the material depleted of Aβ as ID-AD.  ID and AD samples from 412 
AD1 were analyzed using IP/WB, and MSD immunoassays that preferentially recognize 413 
either Aβ oligomers (oAssay) or Aβ42 monomers (Mc Donald et al., 2015).  IP/WB 414 
analysis allows the capture of Aβ structures under native conditions and their detection 415 
following denaturing SDS-PAGE.  We were careful to also determine if AW7 altered 416 
APP metabolites present in AD brain extracts that contained all or part of the Aβ 417 
sequence i.e. APPs, N-terminally extended Aβ (-31Aβ40), or so-called A peptides.  418 
To this end AW7 IPs were used for Western blotting with (i) the C-terminal anti-Aβ 419 
antibodies, 2G3 and 21F12, and (ii) the N-terminal anti-Aβ antibody, 6E10.  The latter, 420 
but not the former, reacts with APPs and A peptides (Portelius et al., 2013; Welzel 421 
et al., 2014; Willem et al., 2015).  6E10 readily detected ~4 kDa Aβ, but it did not detect 422 
 23 
 
any bands consistent with APPs or A.  Furthermore, direct Western blot analysis of 423 
AD brain extract demonstrated highly similar levels of APPs in both AW7 and mock 424 
immunodepleted extracts.  Thus, it appears that AW7 does not deplete AD extracts of 425 
non-Aβ APP metabolites that contain the N-terminal portion of Aβ (Figure 2A).  The ~7 426 
kDa Aβ species detected with 2G3 and 21F12 was not detected with 6E10, consistent 427 
with our prior observation that most ~7 kDa Aβ is N-terminally truncated - a pattern we 428 
have seen in aqueous extracts of more than 100 AD brains analyzed in our laboratory 429 
(Mc Donald et al., 2015).  Since SDS-PAGE is highly denaturing, the ~4 and ~7 kDa 430 
species do not necessarily reflect native Aβ species.  Rather, these simply indicate that 431 
at least two different Aβ species are present.  The same samples were treated with or 432 
without 5 M GuHCl and then analyzed using MSD assays.  In prior studies we found 433 
that GuHCl effectively disaggregates high molecular weight Aβ species such that the 434 
signal detected by our oAssay is greatly decreased, whereas the signal detected by the 435 
monomer-preferring Aβx-42 immunoassay is proportionately increased (Mably et al., 436 
2015).  A similar outcome was evident when the extract of AD1 was treated with GuHCl 437 
(Figure 2B).  Specifically, GuHCl treatment caused a ~70% decrease in the oligomer 438 
signal and a more than 8-fold increase in the monomer signal.  Together these 439 
immunoassay and IP/WB results indicate that the majority of Aβ in the AD1 extract exist 440 
as labile aggregates made up of ~4 kDa Aβ and ~7 kDa Aβ.  Importantly, AW7 ID 441 
effectively removed the large majority of the various Aβ species detected (Figure 2A 442 
and B).  For instance, AW7 ID reduced the oligomer signal from 5.1 ± 0.03 ng/ml to 0.32 443 
± 0.12 ng/ml (Figure 2B, left panel) and monomer from 3.42 ± 0.03 ng/ml to 0.12 ± 0.04 444 
ng/ml (Figure 2B, right panel). 445 
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For slices that received vehicle aCSF-B (Control), TBS induced strong potentiation 446 
which lasted the whole recording period (Figure 2C, black circles, 181.1 ± 10.7 %, n = 447 
17), and ID-AD1 allowed a similar response (green downward triangles, 173.6 ± 8.7 %, 448 
n = 11, p=0.12, One-Way ANOVA) (Figure 2C and D).  Consistent with prior reports 449 
(Shankar et al., 2008; Freir et al., 2011), application of the AD1 (magenta diamonds) 450 
extract significantly decreased LTP compared to both the control and ID-AD1 treatment 451 
(136 ± 4.2 %, n = 18, F=4.26，p=6.98E-9 AD1 vs. Control; F=4.14, p=3.56E-12 AD1 vs. 452 
ID-AD1, One-Way ANOVA).  The fact that the ID-AD1 and AD1 samples are identical 453 
except that the latter contains more Aβ than the former, is evidence that some form of 454 
Aβ is responsible for the block of LTP induced by the AD1 extract.  To further test the 455 
Aβ dependency of the block of LTP mediated by AD1, we examined whether an extract 456 
from a non-AD brain (NC), could impair LTP.  As anticipated, the NC extract lacked 457 
appreciable levels of Aβ (not shown) and did not impair LTP (Figure 2E and F, 159.54 ± 458 
10.6 % in NC, n = 8; 160.36 ± 6.26 % in Control, n = 8; F=4.6，p=0.95 One-Way 459 
ANOVA). 460 
 461 
Aβ-containing AD brain extract affects pre-synaptic release probabilities 462 
Accumulating evidence indicates that soluble Aβ species may interact with excitatory 463 
and inhibitory pre-synaptic terminals, modulate neurotransmitter release and cause 464 
synaptic dysfunction in the very early stages of AD (Nimmrich et al., 2008; Abramov et 465 
al., 2009; Kabogo et al., 2010; Parodi et al., 2010; Russell et al., 2012; Sokolow et al., 466 
2012; Huang et al., 2013; Ripoli et al., 2013; Kurudenkandy et al., 2014).  Although the 467 
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effects of Aβ on LTP are well established (Klyubin et al., 2012), little is known about 468 
whether and how Aβ-containing AD extracts affect pre- and post-synaptic elements.  To 469 
investigate effects on pre-synaptic release, we measured short-term synaptic facilitation 470 
(Zucker and Regehr, 2002) in slices before and 30 minutes after treatment with AD1 471 
extract.  As synapse release probability is inversely correlated to synaptic facilitation 472 
(Zucker and Regehr, 2002), we employed high-frequency burst stimulation (5 pulses 473 
with 20 millisecond intra-burst stimulus interval).  Application of AD1 extract induced a 474 
reduction in the short-term facilitation during burst stimulation (Figure 3A and B).  When 475 
responses were normalized based on the ratio of each fEPSP to the first response, we 476 
found that treatment with AD1 extract had no effect on the 2nd response, but significantly 477 
decreased the 3rd, 4th, and 5th response (magenta circles, p=0.02 at 3rd stimulation, 478 
p=0.004 at 4th stimulation and p=0.004 at 5th stimulation, n = 6, student’s t-test, and also 479 
by group and time with Two-way ANOVA, F(4,7)=6.39, p=0.006) (Figure 3B).  In contrast, 480 
the slices treated with ID-AD1 yielded a pattern highly similar to that obtained with 481 
aCSF-B control (n = 7, F=5.32, p=0.91, Two-Way ANOVA, Figure 3C and D).  Thus, Aβ 482 
in the AD extract caused a reduction in short-term synaptic plasticity associated with 483 
increased pre-synaptic glutamate release. 484 
 485 
Aβ-containing AD brain extract disrupts the excitation-to-inhibition balance 486 
To estimate the effect of Aβ on the total synaptic input at the single-neuron level, we 487 
used whole-cell voltage clamp recordings to measure spontaneous excitatory 488 
postsynaptic currents (sEPSCs) on CA1 pyramidal neurons before and 30 minutes after 489 
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addition of AD extract.  The holding potential was kept constant at -70 mV and sEPSCs 490 
measured before and 30 minutes after addition of AD1 extract – this 30 minutes interval 491 
was chosen to match the pre-incubation time used in our LTP and short-term facilitation 492 
experiments.  Application of the AD1 extract significantly decreased the inter-event 493 
interval (p=1.65E-6, K-S test) and increased the mean frequency of sEPSCs (from 1.8 ± 494 
0.2 Hz to 2.7 ± 0.3 Hz, p=0.02, n = 7, student’s t-test) (Figure 4A and B), but did not 495 
alter the sEPSCs amplitude (mean amplitude from 11.7 ± 1.8 pA to 10.1 ± 1.6 pA, 496 
p=0.65, n = 7, student’s t-test) (Figure 4A and C).  In contrast, the ID-AD1 sample had 497 
no effect on the frequency or the amplitude of sEPSCs (mean frequency: from 2.2 ± 0.5 498 
Hz to 2.3 ± 0.7 Hz, mean amplitude: from 9.7 ± 1.7 pA to 10.2 ± 1.4 pA, p=0.45, n = 6, 499 
student’s t-test) (Figure 4D–F).  These results indicate that the AD brain-derived Aβ 500 
significantly augments excitatory synaptic input on CA1 pyramidal neurons. 501 
Pyramidal neurons receive both excitatory (sEPSCs) and inhibitory (sIPSCs) inputs, 502 
GABAergic axon terminals more easily form synapses with perisomtatic regions of 503 
pyramidal cells and strongly influence the output of neurons (DeFelipe, 2002; Garcia-504 
Marin et al., 2009).  To record sIPSCs on the same neurons, we adjusted the holding 505 
potential to 5 mV, a voltage close to the calculated sEPSCs reverse potential.  As 506 
shown in Figure 4G–I, the AD1 sample significantly increased inter-event intervals 507 
(p=6.19E-6, K-S test) and decreased the frequency of sIPSCs (from 4.7 ± 0.7 Hz to 3.1 508 
± 0.7 Hz, p=0.008, n = 7, student’s t-test), without altering sIPSCs amplitude (from 14.8 509 
± 1.4 pA to 14.2 ± 0.9 pA, p=0.75, n = 7, student’s t-test).  In contrast, the ID-AD1 510 
sample had no effect on sIPSCs (frequency: from 5.3 ± 0.4 Hz to 4.8 ± 0.7 Hz, 511 
amplitude: from 13.6 ± 1.6 pA to 13.2 ± 2.1 pA, p=0.21, n = 6, student’s t-test) (Figure 512 
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4J-L).  These results revealed that brain-derived Aβ significantly reduces GABAergic 513 
input on CA1 pyramidal cells. 514 
To assess whether the changes of excitatory input (E) and inhibitory input (I) to the 515 
same neuron affect the E/I balance of that neuron, we calculated the integrated 516 
conductance of sEPSCs and sIPSCs over a 5 minutes period (Figure 4M).  Comparison 517 
of the integrated conductance before and 30 minutes after AD1 sample application 518 
revealed E was increased ~3 fold and I was decreased ~50%, consequently, the E/I 519 
balance was increased ~6 fold (n = 7) (Figure 4N).  These results show that AD brain-520 
derived Aβ oppositely affects excitatory and inhibitory synaptic transmission, causing an 521 
increase in the E/I ratio.  These changes, especially the reduction of GABAergic tone on 522 
individual neurons, may contribute to neuronal hyperactivity and disturb network 523 
homeostasis, thereby perturbing LTP (Wang et al., 2014; Gillespie et al., 2016). 524 
 525 
Genetic ablation of APP occludes the effects of Aβ on LTP and pre-synaptic 526 
activity and normalizes the E/I balance 527 
Multiple lines of evidence suggest that the APP may play a role in both GABAergic and 528 
glutamatergic neurotransmission (Bai et al., 2008; Kabogo et al., 2010; Pliassova et al., 529 
2016; Schwenk et al., 2016) and separate studies impute a link between Aβ and APP 530 
(Lorenzo et al., 2000; Fogel et al., 2014; Kirouac et al., 2017).  Thus, having found that 531 
brain-derived Aβ acts on pre-synapses and modulates both GABA and glutamate 532 
transmission, we investigated if APP was required for these effects.  For this, we 533 
employed mice null for APP (Figure 5A).  In agreement with prior reports, brain slices 534 
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from APP KO and WT littermate mice exhibited similar levels of basal activity (p=0.19, 535 
One-Way ANOVA) and LTP (Figure 5B and C) (Dawson et al., 1999; Jedlicka et al., 536 
2012).  In both WT and APP KO slices treated with the aCSF-B control, TBS induced 537 
strong potentiation which lasted the whole recording period (158.1 ± 6.3 % in WT, n = 538 
11, black circles; 151.2 ± 8.5 % in APP KO, n = 9, gray hexagons; F=4.4, p=0.79, 539 
comparison of the last 10 minutes of recording using One-Way ANOVA) (Figure 5C and 540 
D).  In agreement with experiments shown in Figure 2, addition of AD1 extract to WT 541 
slices significantly decreased LTP compared to addition of aCSF-B (121.8 ± 5.4 % in 542 
WT + AD1, magenta diamonds, n = 7, F=4.5, p=0.0005, WT Ctr vs. WT + AD1, One-543 
Way ANOVA).  However, application of the same extract to slices from APP KO mice 544 
had no effect on LTP, with the level of LTP in APP KOs indistinguishable from that of 545 
WT or APP KO treated with aCSF-B control (145.4 ± 4.2 % in APP KO + AD1, pink 546 
upward triangles, F=4.5, p=0.41, APP KO Ctr vs. APP KO + AD1; One-Way ANOVA).  547 
Similarly, when applied to APP KO brain slices, AD1 extract had no effect on short-term 548 
facilitation (Figure 5E and F). 549 
To assess the generalizability of the rescue of LTP by APP ablation, we tested the 550 
effect of an extract from a second AD brain (AD2) on another APP KO mouse line 551 
(Zheng et al., 1995).  As with the AD1 extract (Figure 2), the AD2 and ID-AD2 extracts 552 
were characterized by IP/WB and ELISA.  The profiles obtained for AD2 (Figure 6A) 553 
were similar to those of AD1 (Figure 2A), except AD2 contained relatively more ~7 kDa 554 
species than AD1 (Figure 6 A and B).  As seen with the first APP KO line tested (Figure 555 
5), brain slices from the second APP KO line (which we refer to as Zheng APP KOs) 556 
(Zheng et al., 1995) exhibited similar levels of basal activity as slices from wild type 557 
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mice (F=4.6, p=0.91, One-Way ANOVA) (Figure 6E and F).  When AD2 extract was 558 
applied to slices from WT mice it blocked LTP in an Aβ-dependent fashion (184.1 ± 7.7 % 559 
in WT Ctr, black circles, n = 12; 137.1 ± 7.2 % in WT + AD2, magenta diamonds, n = 12; 560 
F=4.96, p=0.0001, One-Way ANOVA), but had no effect on LTP elicited from APP KO 561 
mice (175.8 ± 9 % in APP KO Ctr, gray hexagons, n = 11; 169.9 ± 4 % in APP KO + 562 
AD2, pink upward triangles, n = 12; F=5.12, p=0.56, One-Way ANOVA) (Figure 7A and 563 
B). 564 
To further examine whether the APP-dependent block of LTP by AD brain extracts was 565 
indeed mediated by A and not some other AW7-reactive material, we tested if the well-566 
established block of LTP mediated by ADDLs (Lambert et al., 1998; Wang et al., 2002; 567 
Lauren et al., 2009; Freir et al., 2011) also required expression of APP.  ADDLs were 568 
prepared as described previously and then assessed using SEC and EM (Figure 6C 569 
and D).  The ADDL preparation contained a mixture of Aβ aggregates and a small 570 
amount of monomer (Figure 6C and D).  When applied to brain slices from WT mice, 571 
ADDLs (200 nM) blocked LTP (188.9 ± 11.5 % in WT Ctr, black circles, n = 8; 123.8 ± 6 % 572 
in WT + ADDLs, magenta diamonds, n = 6; F=4.75, p=0.0007, One-Way ANOVA), but 573 
had no effect on LTP elicited from APP KO slices (181.5 ± 15 % in APP KO Ctr, gray 574 
hexagons, n = 7; 168.1 ± 10 % in APP KO + ADDLs, pink upward triangles, n = 7; 575 
F=4.85, p=0.07, One-Way ANOVA) (Figure 7C and D).  Thus, it appears that the well-576 
documented plasticity-disrupting activity of both Aβ extracted from AD brains (Klyubin et 577 
al., 2008; Shankar et al., 2008; Barry et al., 2011; Freir et al., 2011; Klyubin et al., 2012) 578 
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and synthetic Aβ (Lambert et al., 1998; Wang et al., 2002; Lauren et al., 2009; Freir et 579 
al., 2011) require expression of APP. 580 
To investigate whether APP is necessary for the effect of Aβ on the E/I balance (Figure 581 
3), we studied the effects of Aβ on sEPSCs and sIPSCs in brains of Zheng APP KO and 582 
WT littermate mice (Figure 8).  When applied to WT slices, AD1 extract again increased 583 
mean sEPSC frequency (from 2.2 ± 0.1 Hz to 3.4 ± 0.2 Hz, p=0.003, n = 5, student’s t-584 
test) and decreased inter-event intervals (p=6.34E-15, K-S test), without altering the 585 
amplitude of sEPSCs (mean amplitude: 17.8 ± 0.4 pA vs. 18 ± 1.5 pA, p=0.32, n = 5, 586 
student’s t-test) (Figure 8A-C); and on the same neuron decreased mean sIPSCs 587 
frequency (from 4.2 ± 0.8 Hz to 2.7 ± 0.4 Hz, p=0.006, n = 5, student’s t-test) and 588 
increased inter-event intervals (p=9.44E-20, K-S test), but not amplitude (mean 589 
amplitude from 20 ± 3 pA to 19.3 ± 1.3 pA, p=0.34, n = 5, student’s t-test) (Figure 8D-F).  590 
These results, which were obtained with WT mice from an entirely different colony as 591 
those used in Figure 2, nicely demonstrate the robustness of the Aβ effect (See Figure 592 
4 vs. Figure 8).  Most importantly, when AD1 extract was applied to Zheng APP KO 593 
slices there was no change in the frequency or amplitude of sEPSCs (mean frequency: 594 
from 2.6 ± 0.1 Hz to 2.7 ± 0.4 Hz, mean amplitude: from 15 ± 1.4 pA to 14.6 ± 0.5 pA, 595 
p=0.14, K-S test; p=0.26, n = 6, student’s t-test) (Figure 8G-I).  Similarly, sIPSCs were 596 
also unchanged (mean frequency: from 3.5 ± 0.5 Hz to 3.5 ± 0.3 Hz, mean amplitude: 597 
from 16.7 ± 1 pA to 16.4 ± 1.6 pA, p=0.58, K-S test; p=0.25, n = 6, student’s t-test 598 
(Figure 8J-L).  Thus, as with our LTP experiments (Figures 5 and 7), ablation of APP 599 
completely rescued the effects of Aβ on excitatory and inhibitory input on CA1 pyramidal 600 
neurons.  Further, since APP KO occluded Aβ alterations on the E and I input at 601 
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individual neurons, it also prevented Aβ-mediated changes in the integrated 602 
conductance of sEPSCs and sIPSCs (Figure 8M).  When AD1 extract was applied to 603 
WT slices, E increased ~3-fold and I decreased ~44%, resulting in ~5.8-fold increase in 604 
the E/I ratio.  However, APP KO significantly prevented those E/I ratio changes 605 
(p=0.001, E/I in WT vs. E/I in APP KO, One-Way ANOVA) (Figure 8M).  These results 606 
indicate that APP plays an important role in regulating the acute effects of Aβ on 607 
excitatory and inhibitory pre-synaptic release, and consequent maintenance of network 608 
homeostasis. 609 
 610 
Aβ binding to synapses requires APP 611 
To further investigate the targeting of synaptic elements by Aβ and how this might be 612 
influenced by APP we used a powerful high-resolution microscopic technique, array 613 
tomography (AT), to search for evidence of Aβ binding to synapses in the same brain 614 
slices used in our electrophysiology experiments.  Upon completion of LTP recording, 615 
certain slices from the treatment groups used in Figures 2C and 5C were immediately 616 
fixed, processed and used for AT.  Sections were stained with 1C22 – the same 617 
aggregate-preferring antibody (Mably et al., 2015; Pickett et al., 2016) used in our 618 
oAssay, anti-synapsin-1 (for pre-synapses) and anti-PSD95 (for post-synapses).  619 
Approximately 7,000 synapses (~3,500 pre-synapses and ~3,500 post-synapses) per 620 
slice were analyzed for a total of 100,359 pre-synapses and 99,075 post-synapses.  AT 621 
revealed, significant anti-Aβ staining at synapse of slices incubated with AD1 extract, 622 
with only background staining in samples incubated with aCSF controls and ID-AD1 623 
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(Figure 9A-C; Kruskal Wallis test for synapsin-1 (χ2(4)=10.844, p=0.028), Kruskal Wallis 624 
test for PSD95 (χ2(4)=11.583, p=0.021)).  In slices incubated with AD1 extract 1.27 ± 625 
0.47% of pre-synapses and 0.58 ± 0.19% of post-synapses stained with 1C22, whereas 626 
in slices that had been incubated with aCSF, only 0.0076 ± 0.013% of pre-synapses 627 
and 0.0184 ± 0.087% of post-synapses were 1C22 positive (Dunns post-hoc between 628 
AD and control for pre-synapses p=0.024 and for post-synapses p=0.010).  Slices 629 
incubated with extracts immunodepeleted of Aβ exhibited similar background staining 630 
with 1C22 as the aCSF control (Figure 9A-C).  Thus, the same treatment with AD1 631 
extract that disrupts synaptic plasticity in an Aβ-dependent fashion (Figures 2 and 4) 632 
also leads to Aβ binding to synapses (Figure 9A-C).  Moreover, the finding that Aβ is 633 
present at more pre-synapses than post-synapses (Mann-Whitney U between AD pre-634 
synapses and AD post-synapses U=0, p=0.004) is consistent with our results that 635 
suggest a pre-synaptic effect of Aβ (Figures 4 and 8), and with preliminary experiments 636 
using an antibody to another pre-synaptic marker, synaptophysin. 637 
The number of Aβ positive synapses detected here is much lower than the amount of 638 
Aβ observed at synapses when synthetic oligomers are applied to cultured hippocampal 639 
neurons (Lacor et al., 2004; Lacor et al., 2007).  However, the current paradigm, of 640 
applying soluble AD brain extract to intact mouse brain slices is more relevant to the in 641 
vivo situation than model systems in which Aβ is applied directly and at high 642 
concentrations to dissociated neurons (Lacor et al., 2004; Lacor et al., 2007).  Indeed, it 643 
is noteworthy that the percentage of synapses positive for Aβ in the current study are 644 
consistent with our findings in APP transgenic mouse brain where we observed 645 
approximately 1% of postsynaptic densities (PSDs) positive for Aβ distant from plaques 646 
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(Koffie et al., 2009).  Similarly, in human AD brain at sites distant from plaques, we 647 
detected Aβ at 0.6% of PSDs and 0.5% of pre-synaptic terminals (Koffie et al., 2012).  648 
Thus, at disease relevant concentrations sufficient to disrupt plasticity, synaptic Aβ 649 
binding occurs at levels similar to that observed in human AD brain. 650 
Importantly, when brain slices from APP KO mice were incubated with AD1 extract, little 651 
or no synaptic 1C22 staining was detected (Figure 9A-C).  These results are notable 652 
since expression of APP was found to be required for Aβ-mediated disruption of both 653 
long-term plasticity (Figures 5 and 7) and neurotransmitter release (Figure 8).  In sum, 654 
our AT data are completely congruent with the results of our electrophysiological 655 
experiments and indicate that expression of APP is required for the binding and 656 
subsequent plasticity-disrupting effects of Aβ, and that these effects are largely 657 
mediated on the pre-synapse. 658 
 659 
APP mediates binding of synaptotoxic Aβ to brain cells 660 
We reasoned that if synaptotoxic forms of Aβ bound to APP or to an APP containing 661 
complex then it should be possible to pre-treat bioactive extracts with a source of APP 662 
to deplete the extract of activity.  One possible approach would be to add exogenous 663 
recombinant APP, but APP is a transmembrane protein and its expression outside of a 664 
membrane environment in the absence of proper post-translational modifications 665 
precludes its use.  Instead, we pre-incubated AD2 extract with either APP-containing 666 
(WT) or APP lacking (KO) brain slices (Figure 10A).  When AD2 was pre-incubated with 667 
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WT brain slices and then applied to a fresh WT brain slice it was no longer capable of 668 
blocking LTP (216.4 ± 26 % in WT slices + AD2, green upward triangles, n = 6; F=4.96, 669 
p=0.82, One-Way ANOVA) (Figure 10B and C).  In contrast, when AD2 extract was pre-670 
incubated with APP KO slices and then applied to a fresh WT brain slice, the AD2 671 
extract retained its ability to block LTP (210.3 ± 15 % in WT Ctr, black circles, n = 6; 672 
146.8 ± 5.4 % in APP KO +AD2, magenta diamonds, n = 6; F=4.96, p=0.003, One-Way 673 
ANOVA, Figure 10B and C).  These results are entirely consistent with our array 674 
tomography experiments and provide further evidence that APP enables synaptotoxic 675 
forms of Aβ to bind to and perturb neurons. 676 
 677 
Aβ-containing AD brain extract partially blocks LTP in APP hemizygous brain 678 
slices 679 
To further investigate the requirement of APP for Aβ synaptotoxicity, we tested the 680 
effect of AD2 extract on brain slices from APP hemizygous mice.  APP expressing wild 681 
type C57BL/6 were bred with Zheng APP KO mice and the hemizygous progeny used 682 
for LTP experiments.  Hemizygous mice express 50% as much APP as WT mice 683 
(Figure 11A) and exhibit similar levels of basal activity relative to slices from wild type 684 
mice (F=4.6, p=0.75, One-Way ANOVA) (Figure 11B).  The control level of LTP was 685 
also similar in WT and hemizygous brain slices (187.85 ± 5.63 % in WT Ctr, black 686 
circles, n = 9; 189.69 ± 7.19 % in hemizygous brain slices, gray hexagons, n = 9; 687 
F=4.45, p=0.84, One-Way ANOVA) (Figure 11C and D).  When AD2 extract was 688 
applied to slices from WT mice it blocked LTP to an extent comparable to that seen in 689 
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previous experiments (compare Figure 11C and D versus Figure 7A and B) (187.85 ± 690 
5.63 % in WT Ctr, black circles, n = 9; 136.93 ± 3.14 % in WT + AD2, magenta 691 
diamonds, n = 10; F=4.5, p=2.67E-007, One-Way ANOVA).  Similarly, AD2 extract 692 
impaired LTP in APP hemizygous mice (189.69 ± 7.19 % in APP +/- Ctr, gray hexagons, 693 
n = 9; 154.83 ± 6 % in APP +/- AD2, pink upward triangles, n = 10; F=4.49, p=0.003, 694 
One-Way ANOVA) (Figure 11C and D).  Although the extent of the block in hemizygous 695 
slices was somewhat reduced compared WT slices (F=4.45, p=0.84, Control in WT 696 
mice vs. Control in APP +/- mice; F=4.5, p=2.67E-007, Control vs. AD2 in WT mice; 697 
F=4.49, p=0.003, Control vs. AD2 in WT mice; One-Way ANOVA), the effect of AD2 698 
extract on hemizygous brain slices stands in contrast to its lack of effect on APP KO 699 
slices (Figure 7A and B).  The partial attenuation of Aβ synaptotoxicity in APP 700 
hemizygous brain indicates a gene-dose effect, such that 50% of the normal level of 701 
APP is sufficient to mediate some block of LTP, but not the full block of LTP seen in 702 
APP WT mice.  Further studies will be required to determine the minimal reduction in 703 
APP levels that allows full protection against the plasticity disrupting effects of Aβ. 704 
705 
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Discussion 706 
To better understand how Aβ disrupts synaptic plasticity we combined the use of the 707 
most disease relevant form of Aβ, material extracted from human AD brain, with 708 
electrophysiological approaches and high-resolution microscopy.  Consistent with prior 709 
studies, we show that extracts from the brains of individuals who died with AD block 710 
LTP (Shankar et al., 2008; Barry et al., 2011; Freir et al., 2011; Yang et al., 2017).  We 711 
further show that, concomitant with the block of LTP, there is an increase in pre-712 
synaptic release and disruption of E/I balance.  In accord with these synaptic effects of 713 
Aβ, we demonstrate that exogenously applied AD brain-derived Aβ binds to synapses, 714 
with more Aβ oligomers detected on pre-synapses than on the post-synapses.  Our 715 
finding that treatment with brain-derived Aβ enhances excitatory drive agrees well with 716 
studies showing that aggregated forms of synthetic Aβ increase EPSPs, action 717 
potentials, and membrane depolarizations (Hartley et al., 1999; Minkeviciene et al., 718 
2009; Kurudenkandy et al., 2014).  Our study is unique in that we employed brain-719 
derived Aβ, and that the concentration of this material was much lower than the 720 
synthetic Aβ used in prior studies.  In support of the strength of this experimental 721 
paradigm, the levels of synaptic Aβ we observe in this study are very similar to those 722 
observed with array tomography in our studies of human AD brain (Koffie et al., 2012). 723 
The apparent paradox that ectopic application of Aβ causes a net increase in excitation, 724 
yet impairs LTP may result because of glutamate spillover and activation of extra- or 725 
perisynaptic NR2B-enriched NMDARs, which play a major role in LTD induction (Li et 726 
al., 2011; Zhang et al., 2016).  In such a scenario, synaptic depression may result from 727 
an initial increase in synaptic activation of NMDARs by glutamate, followed by synaptic 728 
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NMDAR desensitization, NMDAR/AMPAR internalization, and activation of 729 
extrasynaptic NMDARs and mGluRs (Born et al., 2014).  However, it is unclear why 730 
ablation of APP could recover such effects. 731 
An alternative explanation that accounts for a role for APP in the impairment of post-732 
synaptic efficacy is that exogenous AD brain-derived soluble aggregates and 733 
endogenously produced monomer have differential effects.  Aβ is known to be released 734 
in an activity-dependent manner (Kamenetz et al., 2003; Cirrito et al., 2005), whereas 735 
elevated Aβ levels result in depressed glutamatergic synaptic transmission and 736 
glutamate receptor endocytosis (Kamenetz et al., 2003; Hsieh et al., 2006).  Thus, it is 737 
plausible that the increase in glutamate release induced by soluble Aβ aggregates may 738 
also lead to an increase in de novo Aβ monomer production and this in turn may 739 
depress post-synaptic activity.  Such a scenario would necessarily require expression of 740 
endogenous APP and explain why ablation of APP can obviate the block of LTP caused 741 
by brain-derived soluble Aβ aggregates.  The fact that Aβ treated APP hemizygous 742 
slices exhibited an attenuated block is consistent with a partial reduction in the amount 743 
of endogenous Aβ.  With regard to the protection of LTP upon ablation of APP, it is 744 
important to emphasize the robust nature and generalizability of this phenomenon.  We 745 
observed the same protection using two different APP KO mouse lines (Zheng et al., 746 
1995; Callahan et al., 2017), extracts from 2 different AD brains, and synthetic Aβ 747 
oligomers.  Both AD extracts blocked LTP in an Aβ-dependent manner when applied to 748 
wild type mouse brain slices, but the same AD extracts had no effect on LTP elicited 749 
from APP KO slices.  Moreover, the extent of Aβ binding to synapses was similar in two 750 
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different sources of wild type mice (Figure 7B and C), and the pattern observed was 751 
reminiscent of that seen in AD brain (Pickett et al., 2016). 752 
There is evidence that APP can act as a receptor for Aβ (Melchor and Van Nostrand, 753 
2000; Van Nostrand et al., 2002; Yankner and Lu, 2009; Fogel et al., 2014; Kirouac et 754 
al., 2017) and that APP may mediate increased excitatory drive (Fogel et al., 2014).  755 
Specifically, Aβ was unable to promote aberrant neurotransmitter release in the 756 
absence of APP (Fogel et al., 2014).  Our findings that binding of soluble Aβ aggregates 757 
to synapses requires expression of APP and that synaptotoxic Aβ can be bound by APP 758 
expressing, but not APP lacking brain tissue, are consistent, but not proof, that APP 759 
may act as a receptor for Aβ.  In this regard, it is worth noting that APP is known to both 760 
regulate L-type calcium channels in GABAergic neurons, interact with the pore-forming 761 
subunit Cav1.2 (Yang et al., 2009), and is a member of the GABAB-R receptor complex 762 
(Schwenk et al., 2016).  In addition, there is evidence from proteomic studies indicating 763 
that APP interacts with more than 30 different proteins including proteins key to synaptic 764 
vesicle turnover (Kohli et al., 2012; Del Prete et al., 2014; Lassek et al., 2014; Wilhelm 765 
et al., 2014), and proteins (such as the prion protein) implicated in binding Aβ (Bai et al., 766 
2008; Lauren et al., 2009).  Thus, Aβ could exert an APP-dependent effect either by 767 
directly binding to APP or binding to protein complexes of which APP is a component 768 
and stabilizing member.  The APP gene-dose dependent response to Aβ that we 769 
observed is equally compatible with direct or indirect binding to APP. 770 
So far we have considered the effects of Aβ on synapses and a single hippocampal 771 
pathway (the Schaffer Collateral), but Aβ is also thought to have network-wide effects 772 
(Palop and Mucke, 2010).  For instance, Aβ-induced increases in excitatory network 773 
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activity could lead to synaptic depression through homeostatic mechanisms.  It is well 774 
established that acute treatment of primary neurons with bicuculline (a GABAA 775 
antagonist) increases overall neuronal activity and firing rates (Vertkin et al., 2015).  776 
However, after a few days, neuronal activity returns to control levels.  By analogy, it is 777 
reasonable that the disruption of E/I balance seen with our acute Aβ treatment may also 778 
cause both short-term local and long-lasting network effects.  Given the fact that Aβ 779 
treatment increases excitatory drive and decreases inhibitory drive, and that GABA-780 
ergic interneurons express high levels of APP in DG (Wang et al., 2014; Del Turco et al., 781 
2016) it is tempting to speculate that Aβ-mediated disruption of GABA-ergic 782 
interneurons may play a critical role in the cognitive impairment that occurs early in AD 783 
(Gillespie et al., 2016).  Clearly, further studies will be required to delineate the influence 784 
of APP on both network regulation and other forms of synaptic plasticity, such as LTD. 785 
Considerable data from the study of APP transgenics implicate impairment of 786 
GABAergic interneurons as central to the network disturbances evident in these models 787 
(Busche and Konnerth, 2015; Palop and Mucke, 2016).  However, the unphysiological 788 
expression of high levels of APP and the concomitant release of Aβ from the expressed 789 
transgene make it difficult to differentiate between effects mediated by Aβ versus APP, 790 
or non-Aβ APP metabolites (Melnikova et al., 2013; Born et al., 2014; Fowler et al., 791 
2014).  Nonetheless, growing evidence suggests that GABAergic interneurons play a 792 
prominent role in homeostatic regulation of hippocampal networks, and there is 793 
compelling proteomic and physiological data that link APP and GABAB1a-R (Wang et al., 794 
2014; Gillespie et al., 2016; Schwenk et al., 2016).  Consequently, further investigations 795 
on how Aβ effects GABAB-R expression, GABAB-R-APP interactions and whether 796 
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GABAB-R KOs are resistant to Aβ are merited and may lead to a pharmacological 797 
means to attenuate Aβ synaptotoxicity.  Similarly, modulation of APP expression may 798 
also offer therapeutic potential.  However, while our results demonstrate that ablation of 799 
APP in brain slices from young (2-3 months) mice protects against the acute 800 
synaptotoxicity of Aβ, widespread knock-out of APP is not recommended.  APP appears 801 
to be involved in many physiological processes (Yang et al., 2009; Muller and Zheng, 802 
2012; Del Prete et al., 2014; Lassek et al., 2014; Wang et al., 2014) and aged APP null 803 
mice exhibit hypersensitivity to kainate-induced seizures (Steinbach et al., 1998), 804 
altered exploratory behavior, deficits in spatial memory, and impairment of LTP 805 
(Dawson et al., 1999; Seabrook et al., 1999; Ring et al., 2007).  No such deficits have 806 
been reported in APP hemizygous mice. Thus, it may be possible to down regulate APP 807 
expression so as to maintain normal function, yet attenuate Aβ synaptotoxicity.  808 
However, hemizygous reduction of APP allows only partial protection against the 809 
plasticity disrupting effects of Aβ, and further studies will be required to determine the 810 
minimal reduction in APP levels that allows a more fulsome protection. 811 
 812 
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Figure Legends 813 
 814 
Figure 1.  Processing of array tomography images. 815 
Fields of 10 μm by 10 μm are cropped from an image stack, these are then made into 816 
binary stacks in image J and processed in MATLAB to remove objects not found in 817 
serial slices.  Scale bar is 2 μm. 818 
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Figure 2.  The water-soluble extract of AD brain，  but not normal control, 819 
contains both Aβ monomers and oligomers and perturbs long-term synaptic 820 
plasticity. 821 
(A) Aqueous extract of AD1 was treated with either pre-immune rabbit serum or with 822 
AW7 antiserum.  Portions of the mock immunodepleted sample (AD1, magenta) and the 823 
AW7 immunodepleted sample (ID-AD1, green) were then analyzed by IP/WB, using 824 
AW7 for IP and a combination of 2G3 and 21F12 (left panel), or 6E10 (right panel) for 825 
WB.  M denotes Aβ monomer and  indicates a broad smear ~7–8 kDa.  Synthetic A1-826 
42, -31A40 and Aα each at 2 ng/lane were used as controls.  As expected 6E10 827 
detected all 3 synthetic peptides, whereas 2G3/21F12 detected A1-42, -31A40 but 828 
not Aα.  Only non-specific (NS) bands were detected above 16kDa marker.  (B) AD1 829 
(magenta) and ID-AD1 (green) samples were incubated +/- 5 M GuHCl and analyzed 830 
using immunoassays that preferentially recognize Aβ oligomers (1C22-3D6b, left panel) 831 
or Aβ42 monomer (266-21F12b, right panel). Values shown are the mean ± SEM of 832 
duplicate measurements and are representative of 2 separate experiments.  (C) Time 833 
course plots show that the AD sample but not the ID-AD sample blocked hippocampal 834 
LTP.  The gray horizontal bar indicates the time period when sample was present in the 835 
bath.  1, 2, indicate example traces from time points just prior to the theta burst 836 
stimulation ( TBS) (1) and 60 minutes after TBS (2), respectively.  The aCSF control 837 
is shown in black circles; AD treatment is shown in magenta diamonds and ID-AD with 838 
green downward triangles.  Each slice used for each treatment was from a different 839 
animal.  Scale bar 0.2 mV, 10 milliseconds.  (D) Histogram plots of the average 840 
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potentiation for the last 10 minutes of traces shown in C.  Treatment of slices with AD1 841 
sample significantly inhibited LTP compared to the aCSF vehicle control (F=4.26，842 
p=6.98E-9) and ID-AD1 treatment (F=4.14, p=3.56E-12); in contrast ID-AD1 had no 843 
effect on LTP relative to the vehicle control (F=4.23, p=0.12, One-Way ANOVA).  844 
Symbols are the same as in panel C.  (E) Time course plots show that the brain extract 845 
from a cognitively intact non-AD control (NC) did not blocked hippocampal LTP.  The 846 
gray horizontal bar indicates the time period when sample was present in the bath.  1, 2, 847 
indicate example traces from time points just prior to the theta burst stimulation ( 848 
TBS) (1) and 60 minutes after TBS (2), respectively.  The aCSF control is shown in 849 
black circles; NC treatment is shown in gray hexagons.  Each slice used for each 850 
treatment was from a different animal.  Scale bar 0.5 mV, 10 milliseconds.  (F) 851 
Histogram plots of the average potentiation for the last 10 minutes of traces shown in E 852 
and average of last 10 minutes from individual experiment in every group.  Treatment of 853 
slices with NC sample did not inhibited LTP compared to the aCSF vehicle control 854 
(F=4.6, p=0.95, One-Way ANOVA).  Symbols are the same as in panel E.  Values 855 
shown are the mean ± SEM. ### p<0.001 856 
  857 
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Figure 3.  The A-containing water-soluble extract of AD1 perturbs short-term 858 
facilitation. 859 
(A) Representative traces of averaged field recordings were collected after 5 stimulation 860 
bursts (inter-stimulation interval 20 milliseconds, inter-burst interval 30 seconds) before 861 
(black, aCSF) and 30 minutes after perfusion with the AD1 sample (magenta). The trace 862 
shown for the AD1 samples are scaled so that the first response matches that of the 863 
aCSF control.  Scale bars: 0.5 mV, 10 milliseconds.  (B) fEPSPs amplitude after 2 to 5 864 
stimulations were normalized to the value obtained after the first stimulation.  Compared 865 
to vehicle control, AD1 treatment induced a small but significant decrease in short-term 866 
synaptic facilitation, (p=0.02) after the 3rd, (p=0.004) the 4th stimulation and 5th 867 
stimulation (p=0.004); n = 6, student’s t-test.  Values shown are the mean ± SEM.  # p< 868 
0.05; ## p<0.01.  (C) Representative traces of averaged field recordings were collected 869 
after 5 stimulation bursts (inter-stimulation interval 20 milliseconds, inter-burst interval 870 
30 seconds) before (black, aCSF) and 30 minutes after perfusion with the ID-AD1 871 
sample (green).  Scale bars: 0.4 mV, 10 milliseconds.  ID-AD1 treatment did not affect 872 
short-term synaptic facilitation (n = 5, F=5.32, p=0.91, One-Way ANOVA). 873 
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Figure 4.  AD brain-derived Aβ affects both excitatory and inhibitory synaptic 874 
inputs, causing disruption of the excitatory/inhibitory ratio at individual CA1 875 
neurons. 876 
(A, D) Example traces of spontaneous excitatory post-synaptic currents (sEPSCs) 877 
before (aCSF, black) and 30 minutes after addition of sample (AD1, magenta; ID-AD1, 878 
green) recorded from individual pyramidal neurons in the hippocampal CA1 area of 879 
brain slices with the holding potential fixed at -70 mV.  Scale bars: 20 pA, 700 880 
millisecond.  (B) 30 minutes of AD1 treatment decreased cumulative distributions of 881 
inter-event intervals and increased mean frequency (insert) (p=1.65E-6, K-S test; p< 882 
0.02, student’s t-test; n = 7), but (C) did not change the cumulative distributions or the 883 
mean value (insert) of the amplitude of sEPSCs (n = 7).  (E, F) The ID-AD1 sample had 884 
no effect on either frequency or amplitude of sEPSCs (n = 6).  (G, J) Example traces of 885 
spontaneous inhibitory post-synaptic currents (sIPSCs) before (aCSF, black) and 30 886 
minutes after treatment (AD1, magenta; ID-AD1, green) were recorded on the same 887 
individual pyramidal neurons upon increasing the holding potential to 5 mV.  Scale bars: 888 
20 pA, 700 milliseconds.  (H) 30 minutes of treatment with the AD1 sample increased 889 
inter-event intervals and decreased mean frequency (insert) of sIPSCs (magenta) 890 
versus aCSF (black) (p=6.19E-6, K-S test; p=0.008, student’s t-test; n = 7).  (I) 891 
Treatment with the AD1 sample did not affect the amplitude of sIPSCs (n = 7) and the 892 
ID-AD1 sample had no effect on frequency (K) or the amplitude (L) of sIPSCs versus 893 
aCSF control (n = 7).  (M) Representative traces of sIPSCs and sEPSCs from the same 894 
pyramidal neuron show charge transfer measured as the area of events above 895 
threshold in the aCSF control.  Scale bars: 10 pA, 200 milliseconds.  (N) Integrated 896 
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conductances measured between 30 - 35 minutes after addition of AD1 application 897 
were normalized to the value of 5 minutes before addition of AD1.  Mean excitatory 898 
integrated conductance increased and mean inhibitory integrated conductance 899 
decreased upon treatment of AD1 (E: excitatory input/sEPSCs; I: inhibitory 900 
input/sIPSCs).  Each slice used for each treatment was from a different animal. # p< 901 
0.05, ## p< 0.01. 902 
 903 
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Figure 5.  Expression of APP is required for the plasticity-disrupting activity of 904 
Aβ-containing AD brain extract. 905 
(A) Detergent extracts of mouse brain slices used for electrophysiology were analyzed 906 
for APP by Western blotting with 22C11.  Full-length APP was readily detected in 907 
extracts from wild type littermate mice (WT) but not APP knockout mice (APP KO).  908 
Slices from 2 APP KO mice (KO1 and KO2) and 2 WT mice (WT1 and WT2) are shown.  909 
(B)  Input/output curves recorded in the hippocampal CA1 area are highly similar for 910 
both WT and APP KO mouse brain slices (p=0.19, One-Way ANOVA).  Values are 911 
mean ± SEM.  (C) LTP recorded in hippocampal CA1 was similar in brain slices from 912 
WT and APP KO mice (WT Ctr, black circles vs. APP KO Ctr, gray hexagons, p=0.79, 913 
comparison of the last 10 minutes recording using One-Way ANOVA).  However, the 914 
extract from AD1 brain blocked LTP in WT but not in APP KO mice brain slices.  915 
Horizontal gray bar indicates the duration in which sample was present.  1 and 2 916 
indicate example traces from time points just prior to the theta burst stimulation ( 917 
TBS) (1) and 60 minutes after TBS (2), respectively.  The aCSF control in WT mice is 918 
shown with black circles; AD1 treatment in WT mice is shown in magenta diamonds; the 919 
aCSF control in APP KO mice is shown in gray hexagons and AD1 treatment in APP 920 
KO mice is shown using pink upward triangles.  WT slices for each treatment came from 921 
different animals; the APP KO slices came from a total of 4 APP KO mice.  Scale bars: 922 
0.5 mV, 15 milliseconds.  (D) Comparison of average potentiation from last 10 minutes 923 
of LTP recording (F=4.5, p=0.0005, Control vs. AD1 in WT mice; F=4.5, p=0.41, Control 924 
vs. AD1 in APP KO mice; One-Way ANOVA).  Symbols correspond to those in panel C.  925 
(E) Representative traces of averaged field recordings were collected after 5 stimulation 926 
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bursts (inter-stimulation interval 20 millisecond, inter-burst interval 30 seconds) before 927 
(gray, aCSF) and 30 minutes after perfusion with the AD1 sample (pink) on brain slices 928 
from APP KO mouse.  Scale bars: 0.5 mV, 10 millisecond.  (F) fEPSPs amplitude after 929 
2 to 5 stimulations were normalized to the value obtained after the first stimulation.  930 
There is no significant difference between aCSF control and the presence of AD1 brain 931 
extract application (n = 5, F=5.32, p=0.7, One-Way ANOVA).  Values are mean ± SEM.  932 
Each slice used for each treatment was from a different animal. ### p<0.001. 933 
 934 
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Figure 6.  Characterization of the aqueous extract from AD2 brain, synthetic Aβ 935 
oligomers, and second APP KO mouse line.  (A) Aqueous extract of AD2 was 936 
treated with either pre-immune serum or with AW7 antiserum.  Portions of the mock 937 
immunodepleted sample (AD2, magenta) and the AW7 immunodepleted sample (ID-938 
AD2, green) were then analyzed by IP/WB, using AW7 for IP and a combination of 2G3 939 
and 21F12 (left panel), or 6E10 (right panel) for WB.  As expected, recombinant A 940 
was detected by 6E10, but not 2G3/21F12.  M denotes Aβ monomer and  indicates a 941 
broad smear ~7–8 kDa.  Only non-specific (NS) bands were detected above 16 kDa 942 
marker.  (B) AD2 (magenta) and ID-AD2 (green) samples were incubated +/- 5 M 943 
GuHCl and analyzed using an immunoassay that preferentially recognizes Aβ42 944 
monomer (266-21F12b). AW7 ID reduced monomer from 6.65 ± 0.01 ng/ml to 945 
undetectable level without GuHCl treatment. Upon treatment with GuHCl, the amount of 946 
Aβ42 increased to 46.94 ± 0.2 ng/ml in AD2 and this was reduced to 8.62 ± 0.1 ng/ml by 947 
immunodepletion.  (C) Size-exclusion chromatography of ADDLs revealed a prominent 948 
high molecular weight peak, a trail of intermediate molecular weight species and a small 949 
Aβ monomer peak.  (D) Negative contrast electron micrograph shows mostly protofibril-950 
like structures.  Scale bar is 50 nm.  (E) Brain slices from wild type (WT) and a second 951 
line of APP knock-outs (KO) were analyzed for APP by Western blotting with 22C11.  952 
Full-length APP was readily detected in extracts from WT but not APP KO.  Slices from 953 
2 KO (KO1 and KO2) and 2 WT (WT1 and WT2) mice are shown.  (F) Input/output 954 
curves recorded in the hippocampal CA1 area are highly similar for WT and APP KO 955 
mouse brain slices (F=4.6, p=0.91, One-Way ANOVA).  Values are mean ± SEM. Each 956 
slice used for each treatment was from a different animal. 957 
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Figure 7.  A second APP KO mouse line confirms that APP is required for the 958 
synaptic-disrupting activity of both AD brain and synthetic Aβ oligomers. 959 
(A) LTP recorded in hippocampal CA1 was similar in brain slices from WT and Zheng 960 
APP KO mice.  Notably, the extract from AD2 blocked LTP in brain slices from WT but 961 
not APP KO mice.  Horizontal gray bar indicates the duration during when sample was 962 
present. 1 and 2 indicate example traces from time points just prior to the theta burst 963 
stimulation ( TBS) (1) and 60 minutes after TBS (2), respectively.  The aCSF control 964 
in WT mice is shown with black circles; AD2 treatment in WT mice is shown in magenta 965 
diamonds; ID-AD2 treatment in WT slices in green downward triangles. The aCSF 966 
control in APP KO mice is shown in gray hexagons and AD2 treatment in APP KO mice 967 
is shown using pink upward triangles.  WT slices for each treatment came from different 968 
animals; the APP KO slices came from a total of 6 APP KO mice.  Scale bars: 0.5 mV, 969 
15 millisecond.  (B) Comparison of average potentiation from last 10 minutes of LTP 970 
recording (F=4.96, p=0.0001, Control vs. AD2 in WT mice; F=5.12, p=0.56, Control vs. 971 
AD2 in APP KO mice; One-Way ANOVA).  Symbols correspond to those in panel A.  (C) 972 
ADDLs blocked LTP in WT, but not in APP KO, brain slices.  Horizontal gray bar 973 
indicates the duration during when sample was present. 1 and 2 indicate example 974 
traces from time points just prior to the theta burst stimulation ( TBS) (1) and 60 975 
minutes after TBS (2), respectively.  The aCSF WT slices control is shown with black 976 
circles; WT slices treated with ADDLs is in magenta diamonds; and vehicle in green 977 
downward triangles.  The aCSF control in APP KO mice is shown in gray hexagons and 978 
ADDLs treatment in APP KO mice is shown using pink upward triangles.  WT slices for 979 
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each treatment came from different animals; the APP KO slices came from a total of 6 980 
APP KO mice.  Scale bars: 0.7 mV, 15 millisecond.  (D) Comparison of average 981 
potentiation from last 10 minutes of LTP recording (F=4.75, p=0.0006, Control vs. 982 
ADDLs in WT mice; F=4.75, p=0.93, Control vs. vehicle in WT mice; F=4.84, p=0.07, 983 
Control vs. ADDLs in APP KO mice; One-Way ANOVA).  Symbols correspond to those 984 
in panel C.  Each slice used for each treatment was from a different animal. ### p< 985 
0.001. 986 
 987 
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Figure 8.  APP knock out occludes the effects of Aβ-containing AD brain extract 988 
on both excitatory and inhibitory post-synaptic currents and rescues the 989 
disruption of E/I balance. 990 
(A, D) Example traces of sEPSCs (A) and sIPSCs (D) before (aCSF, black) and 30 991 
minutes after addition of AD1 extract (magenta) on WT hippocampal brain slices.  Scale 992 
bars: 20 pA, 700 millisecond.  (B) Treatment with AD1 extract decreased inter-event 993 
intervals and increased mean frequency (insert) of sEPSCs (p=6.34E-15, K-S test; 994 
p=0.003, student’s t-test; n = 5), but (C) did not significantly change the cumulative 995 
distributions or the mean value (insert) of the amplitude of sEPSCs (n = 5) on WT slices.  996 
(E) 30 minutes of AD1 treatment increased inter-event intervals and decreased mean 997 
frequency (insert) of sIPSCs (p=9.44E-20, K-S test; p=0.006, student’s t-test; n = 5), but 998 
(F) did not affect the cumulative distributions or the mean value (insert) of the amplitude 999 
of sIPSCs (n = 5) on WT slices.  (G, J) Example traces of spontaneous post-synaptic 1000 
currents (sEPSCs, G; sIPSCs, J) before (aCSF, gray) and 30-40 minutes following 1001 
addition of AD1 extract (pink) on APP KO mice hippocampal brain slices.  Scale bars: 1002 
20 pA, 700 millisecond.  (H) Treatment with AD1 sample affected neither frequency nor 1003 
amplitude (I) of sEPSCs (p=0.14, K-S test; p=0.26, student’s t-test; n = 6) on APP KO 1004 
mice.  Similarly, treatment of APP KO neurons with AD1 did not change frequency (K) 1005 
or the amplitude (L, p=0.58, K-S test; p=0.25 student’s t-test; n = 6) of sIPSCs.  (M) 1006 
Application of Aβ-containing AD brain extract significantly changed the integrated 1007 
conductance of both excitatory (E) and inhibitory (I) input to neurons and disrupted the 1008 
E/I balance in WT animals, but not in APP KO mice (p=0.001, E/I in WT vs. E/I in APP 1009 
KO, One-Way ANOVA). 1010 
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Figure 9:  Aβ binding to synaptic terminals requires expression of APP. 1011 
(A) Array tomography of hippocampi stained for synapsin-1 (pre-synapses), Aβ (1C22), 1012 
and PSD95 (post-synapses) reveal co-localization of Aβ at synapses in slices incubated 1013 
with AD1 brain extract.  Images have been processed for analysis as described in the 1014 
methods and Figure 1.  (B and C) The amount of synaptic 1C22 staining was 1015 
significantly greater in slices incubated with AD1 extract than in slices incubated with 1016 
aCSF or ID-AD1 extract based on (B) co-localization of 1C22 and synapsin 1 staining 1017 
(Kruskal Wallis test (χ2(4)=10.844, p=0.028) Dunns post-hoc vs. control p=0.021), and (C) 1018 
1C22 and PSD95 co-localization (Kruskal Wallis test for PSD95 (χ2(4)=11.583, p=0.021; 1019 
Dunns post-hoc vs. control, p=0.01).  Importantly, when slices from APP KO mice were 1020 
incubated with AD1 extract there was no significant co-localization of 1C22 staining with 1021 
either synapsin 1 (B) (Dunns post-hoc vs. control, p=1.000) or PSD-95 (C) (Dunns post-1022 
hoc vs. control, p=1.000).  Graphs represent the medians ± the interquartile range per 1023 
treatment.  Each data point is derived from the analysis of ~3,500 synapses imaged per 1024 
brain slice.  Within each treatment group the 3 slices used were from 3 different mice (B 1025 
and C).  Arrows indicate specific examples of 1C22 staining co-localizing with pre- or 1026 
post-synapses.  Scale bar is 2 m in (A).  # p< 0.05. 1027 
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Figure 10.  APP expressing, but not APP lacking, brain slices bind synaptotoxic 1028 
Aβ. 1029 
(A)  AD2 brain extract was pre-incubated with either 4 WT or 4 APP KO brain slices for 1030 
2 hours and the resultant solutions were used to perfuse WT brain slices.  (B)  Time 1031 
course plots of LTP recorded in WT brain hippocampal CA1 show that AD2 brain extract 1032 
pre-incubated with APP KO brains slices blocked LTP, whereas AD2 pre-incubated with 1033 
WT brain slices allow normal LTP.  Horizontal gray bar indicates the duration during 1034 
when sample was present. 1and 2 indicate example traces from time points just prior to 1035 
the theta burst stimulation ( TBS) (1) and 60 minutes after TBS (2), respectively.  1036 
The aCSF control in WT mice is shown with black circles; AD2 incubated with APP KO 1037 
brain slices in WT mice is shown in magenta diamonds; AD2 pre-incubated with WT 1038 
brain slices is in green downward triangles.  Scale bars: 0.5 mV, 15 millisecond.  (C) 1039 
Comparison of average potentiation from last 10 minutes of LTP recording (F=4.96, 1040 
p=0.003, Control vs. APP KO slices with AD2; F=4.96, p=0.82, Control vs. WT slices 1041 
with AD2; One-Way ANOVA). Symbols correspond to those in panel B.  Each slice 1042 
used for recording for each treatment was from a different animal.  ## p<0.005. 1043 
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Figure 11.  The level of APP expression influences the plasticity-disrupting 1044 
activity of Aβ-containing AD brain extract. 1045 
(A) Detergent extracts of from WT, APP +/- and APP -/- mouse brain slices used for 1046 
electrophysiology were analyzed for APP by Western blotting with 22C11.  Full-length 1047 
APP was readily detected in extracts from wild type mice (WT) and APP +/- mice, but 1048 
not APP -/- mice.  Ten g total protein from APP +/- slices contained a similar amount of 1049 
APP as 5 g total protein from WT slices.  (B)  Input/output curves recorded in the 1050 
hippocampal CA1 area are highly similar for both WT and APP +/- mouse brain slices 1051 
(F=4.6, p=0.75, One-Way ANOVA).  (C) LTP recorded in hippocampal CA1 was similar 1052 
in brain slices from WT and APP +/- mice.  However, AD2 caused a stronger block of 1053 
LTP in WT slices compared with APP +/- slices.  Horizontal gray bar indicates the 1054 
duration during when sample was present.  1 and 2 indicate example traces from time 1055 
points just prior to the theta burst stimulation ( TBS) (1) and 60 minutes after TBS 1056 
(2), respectively.  The aCSF control in WT mice is shown with black circles; AD2 1057 
treatment in WT mice is shown in magenta diamonds; the aCSF control in APP +/- mice 1058 
is shown in gray hexagons and AD2 treatment in APP +/- mice is shown using pink 1059 
upward triangles.  Scale bars: 0.5 mV, 15 milliseconds.  Each slice used for each 1060 
treatment was from a different animal.  (D) Comparison of average potentiation from the 1061 
last 10 minutes of LTP recording (F=4.45, p=0.84, Control in WT mice vs. Control in 1062 
APP +/- mice; F=4.5, p=2.67E-007, Control vs. AD2 in WT mice; F=4.49, p=0.003, 1063 
Control vs. AD2 in WT mice; One-Way ANOVA).  Symbols correspond to those in panel 1064 
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C.  Values are mean ± SEM.  Each slice used for each treatment was from a different 1065 
animal.  ## p<0.005, ### p<0.0001. 1066 
 1067 
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Table 1. Primary and secondary antibodies. 
 
 
 
 
 
 
 
 
Antibody Type Antigen/epitope Dilution 
for IP 
Conc. For 
WB 
Conc. For 
ELISA 
Dilution 
for AT 
Source/Reference 
3D6  Monoclonal Aβ1–5 – - 1 µg/ml – Elan/(Johnson-Wood et al., 1997) 
6E10 Monoclonal Aβ3-8 - 1 µg/ml - - Biolegend/(Kim et al. 1988) 
266 Monoclonal Aβ16-23 – - 3 µg/ml – Elan/(Seubert et al., 1992) 
2G3 Monoclonal Aβ terminating at Val40 – 1 µg/ml – – Elan/(Johnson-Wood et al., 1997) 
21F12 Monoclonal Aβ terminating at Ile42 – 1 µg/ml 1 µg/ml – Elan/(Johnson-Wood et al., 1997) 
1C22 Monoclonal Aβ aggregates – – 3 µg/ml 1:50 Walsh lab/(Mably et al., 2015) 
AW7 Polyclonal Pan anti-Aβ 1:80 – – – Walsh lab/(Mc Donald et al., 2012) 
22C11 Monoclonal APP66-81 – 1 µg/ml – 1:50 Millipore/(Austin et al., 2009) 
AB1543P Polyclonal Rabbit anti-synapsin-1 – – – 1:100 Millipore/(Kay et al., 2013) 
3450P Polyclonal Rabbit anti-PSD95 – – – 1:50 Cell Signaling/(Kay et al., 2013) 
A21202  Polyclonal Donkey anti-mouse 488 – – – 1:50 Invitrogen 
A21207 Polyclonal Donkey anti-rabbit 594 – – – 1:50 Invitrogen 
T6074 Monoclonal Anti-α-Tubulin – 1 µg/ml – – Sigma 











